Becton, Dickinson and Company (BDX)

The share price was $154.96 as of April 7, 2026, a 22.84% decline from $200.83 on April 8, 2025, attributed to the spin-off/merger of its Biosciences division with Waters Corporation in February 2026. BD completed a strategic transformation on February 9, 2026, combining its biosciences and diagnostic solutions businesses with Waters Corporation. On February 10, 2026, BDX executed a stock split with a ratio of 125 for 159. In Q1 2026, adjusted earnings were $2.91 per share, surpassing estimates, with sales reaching $5.25 billion. The updated FY2026 adjusted EPS guidance was $12.35 to $12.65. In late 2024, BD acquired Edwards Lifesciences' critical care unit for $4.2 billion. The BD Alaris™ infusion pump system has been experiencing renewed momentum following regulatory clearances. Recent announcements in April 2026 include BD filing for CE Mark of Liverty TIPS Stent for Portal Hypertension, FDA clearance for Onclarity HPV self-collection kit, and the launch of an AI-Enabled Medication Dispensing System to the European Market.

Available information does not explicitly detail strong demand seasonality for BDX's specific products and services. The nature of medical devices and diagnostic products implies relatively stable demand driven by ongoing healthcare needs rather than seasonal fluctuations. The company's diverse product portfolio across various healthcare segments likely helps mitigate significant overall demand seasonality.

Becton, Dickinson & Company (BDX), also known as BD, is a global medical technology company established in 1897. It operates in the Healthcare sector, focusing on Health Care Equipment and Medical - Dental Supplies. BD's business segments include Medical Essentials, which focuses on high-volume products like syringes and needles; Connected Care, which includes solutions like the Alaris infusion platform; BioPharma Systems, a leader in pre-fillable drug delivery systems; Interventional, providing devices for vascular access and surgical instruments; and Life Sciences, dedicated to diagnostics and research.

BD's headquarters are in Franklin Lakes, New Jersey, USA. The company operates in over 190 countries with manufacturing facilities, distribution centers, and offices across multiple continents. North America, particularly the United States and Canada, is a significant market. Europe includes key countries like the United Kingdom, Germany, France, and Spain. BD is expanding in the Asia-Pacific region, especially in China, India, Japan, and Australia. International revenue accounts for 43% of the company's business.

BD has a long-standing reputation as a global leader in medical technology. The resolution of the Alaris pump regulatory freeze and the strategic transformation focusing on high-margin areas have positively impacted BD's reputation. Innovation in Smart Connected Care and leadership in GLP-1 drug delivery further enhance its brand image. No significant negative events impacting BD's brand reputation were found.

Becton, Dickinson & Co.'s ownership is mainly held by institutional investors, who own a significant portion of the company's shares. As of April 10, 2026, there are 1555 institutional owners holding a total of 264,064,584 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp, T. Rowe Price Investment Management, Inc., First Eagle Investment Management, LLC, Massachusetts Financial Services Co /ma/, Geode Capital Management, Llc, Wellington Management Group Llp, Franklin Resources Inc, and JPMorgan Chase & CO. Insider ownership is minimal, around 0.14% to 0.16%, while retail investors and other shareholders own approximately 20% to 24.81%.